Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 23;10(10):106. doi: 10.1038/s41408-020-00369-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Between June 2018 and January 2019, 293 patients were screened for inclusion in the entire DREAMM-2 study. Between 5 December 2018 and 10 January 2019, 31 patients were screened for inclusion in the lyophilised presentation cohort. b Patients could have more than one reason for exclusion. c Five patients were excluded due to pre-existing corneal disease, as specified in the study protocol. d The remainder of enrolled patients were included in the main DREAMM-2 study previously reported¹⁶. Two patients in the main study were re-randomised and counted twice (once per each randomisation). e One patient was randomised to the belamaf 3.4 mg/kg lyophilised presentation, but actually received 3.4 mg/kg frozen-liquid presentation as first dose, and never received lyophilised presentation during the study.